mercoledì, 25 novembre 2020
11 Dicembre 2018

FDA Approves Frontline Atezolizumab Regimen for NSCLC

December 6, 2018 – The FDA has approved atezolizumab for use in combination with bevacizumab, carboplatin, and paclitaxel (ABCP) for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC). The indication excludes patients with EGFR/ALK aberrations. The approval is based on findings from the phase III IMpower150 trial, in which the ABCP regimen reduced the risk of death by 22% compared with … (leggi tutto)